Why CFOs and CROs Need One View of Medical Trend Outpacing Treaty Economics

The Reprice-Restructure-Hold Decision Every Executive Team Eventually Faces

A medical trend gap does not stay an actuarial problem for long. Once it is quantified, it becomes an executive decision, because every available response, repricing the treaty, restructuring its terms, or holding the current position and absorbing the gap, carries consequences that extend well beyond the numbers.

Capital gets committed or released, client relationships get tested or preserved, and growth plans get accelerated or constrained, depending on which path the executive team chooses. Treating this purely as a technical actuarial fix misses the fact that the real decision sits with people who have to weigh trade-offs an actuarial model alone cannot resolve.

This is exactly the kind of decision that gets made badly by default, not by design, when no one owns the moment it should be forced onto an agenda.

This decision only reaches the executive team once the underlying gap has been diagnosed and quantified, a process covered from the front end in why medical trend outpacing treaty economics goes undiagnosed, and it is structurally the same decision executive teams face with longevity concentration across pension transactions, just triggered by a different underlying risk.

Why Does a Medical Trend Gap Require an Executive Decision Rather Than an Actuarial Fix?

Because the response options, repricing, restructuring, or holding the position, each carry trade-offs in capital, client relationships, and growth strategy that go beyond actuarial judgment alone.

An actuarial team can quantify the size of a trend gap with precision, but deciding what to do about it requires weighing considerations no actuarial model is built to resolve on its own. That includes how a cedant relationship will react to a repricing conversation, how much capital the company wants committed to holding the current position, and how the decision fits into the broader growth strategy for that line of business.

The actuarial diagnosis is a necessary input, but the decision itself belongs at the executive level. A precise number from actuarial without an owner who will act on it is simply a well-documented risk sitting untouched on a shelf.

What Decision Options Does an Executive Team Actually Have?

Reprice the treaty at the next renewal, restructure terms such as attachment points or loading factors, or hold the current terms and absorb the trend gap for a defined period.

Each option carries a distinct trade-off profile. Repricing corrects the gap most directly but risks the cedant relationship and can invite competitive shopping at renewal. Pricing teams running this repricing scenario often lean on the same kind of modeling tooling used for original treaty pricing, such as a Treaty Pricing AI Agent, to test how a revised rate or structure performs against current trend before it reaches the negotiating table.

Restructuring, adjusting an attachment point or loading factor without a full rate change, narrows the gap with less relationship friction but leaves some exposure unaddressed. Holding the position preserves the relationship intact in the short term but means consciously accepting a known, quantified erosion of margin and capital efficiency for as long as the hold lasts, a dynamic explored further from the capital angle in the capital drag created by medical trend outpacing treaty economics.

Why Do CFOs and CROs Need a Shared View Rather Than Separate Reports?

A CFO sees the capital and earnings consequence while a CRO sees the underlying risk trajectory, and a decision made from only one lens routinely misses the trade-off the other lens would catch.

A CFO evaluating this decision through a capital and earnings lens alone might favor immediate repricing to stop the bleeding, without fully weighing how the underlying risk trajectory is expected to evolve. A CRO evaluating it purely through a risk lens might favor holding the position if the trend appears likely to moderate, without fully accounting for the capital cost of waiting.

Neither view alone produces the best decision. A shared, jointly reviewed picture of both the capital consequence and the risk trajectory is what lets the executive team weigh the real trade-off rather than optimizing for only half of it.

In practice, this means a single one-page brief both executives sign off on before a renewal conversation, not two separate departmental memos that never get reconciled.

What Happens If the Decision Is Delayed Until Renewal?

The trend gap keeps compounding every reporting period until renewal, so delaying the decision does not avoid the cost, it just defers when the cost gets recognized.

Waiting for a scheduled renewal to address a known trend gap feels lower-risk in the moment, but it is not actually free. Every reporting period between diagnosis and renewal is another period where the treaty is generating claims cost the pricing was not built to absorb, and another period where capital sits misallocated against the true size of the risk.

The decision to wait is itself a decision, and it should be made deliberately rather than by default.

How Should Client Relationship Risk Factor Into the Decision?

Repricing or restructuring a treaty markedly can strain a cedant relationship, so the executive decision needs to weigh relationship and pipeline value against the financial cost of holding the position.

A cedant relationship that generates significant future pipeline value may justify accepting a larger, temporary margin hit rather than forcing a repricing conversation that risks the relationship entirely. Conversely, a relationship with limited future growth potential may not justify absorbing an ongoing trend gap just to avoid a difficult renewal conversation.

This is precisely the kind of judgment call that belongs with executives who own the relationship and the broader strategic picture, not with an actuarial model alone.

What Does This Trade-Off Look Like Side by Side?

Consider a $40 million treaty running three points hot on trend, worth roughly $1.2 million in annual unpriced claims cost.

Repricing at the next renewal stops the bleeding immediately but risks a cedant that generates $8 million in annual pipeline value across other lines. Restructuring the attachment point might close half the gap, roughly $600,000 a year, while preserving the relationship largely intact.

Holding the position for one more renewal cycle costs the full $1.2 million but buys time to assess whether trend is likely to moderate. None of these is automatically correct, but laid out this way, as dollar figures next to relationship value, the CFO and CRO are debating the same trade-off instead of two different ones.

The clearest sign of a well-run executive process here is not which option gets chosen. It is whether the choice was made deliberately, with a current shared view of the trend gap, its capital cost, and its relationship implications, rather than by default because nobody forced the conversation until renewal made it unavoidable.

A reprice, restructure, or hold decision made early and knowingly is a strategic choice. The same decision made late, after the gap has quietly compounded for several quarters, is just damage control wearing a strategy label.

What Should This Decision Change About Future Treaty Design?

Every time an executive team works through a reprice-restructure-hold decision, the underlying cause is usually the same: the treaty had no mechanism to adjust when trend moved against it.

Building trend-indexed loading factors into new multi-year treaties, where the loading automatically adjusts within a pre-agreed band as actual trend moves, removes much of this decision from being an emergency renegotiation later. Shorter renewal cycles on the specific lines most exposed to medical trend volatility, even if the rest of the book stays on longer terms, is another structural fix that reduces how often this exact executive decision has to be made under pressure.

Treating each trend gap purely as a one-off negotiation misses the more valuable lesson, which is that the treaty design itself should be updated so the next trend surprise does not require the same scramble.

Sources

• HFMA, citing PwC's 2026 medical cost trend survey: "Healthcare costs for businesses to rise 8.5% in 2026"
• Aon: "U.S. Employer Health Care Costs Expected to Rise 9.5 Percent in 2026"